Smaller companies set for third-quarter catalysts
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Asco 2021 justifies Novartis’s radioligand Vision
177Lu-PSMA-617 shows impressive survival results in the Vision study, but early use will be key to fulfilling its potential.
Radiotherapeutics remain in the deal-making frame
A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.
Lynparza’s Olympia win could broaden breast cancer use
The Parp inhibitor registers an unexpected clinical win in the adjuvant setting, but more convincing data might still be needed.
Esmo 2020 preview – a kidney cancer showdown gets star billing
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
Cut-price drug venture takes aim at Pfizer and Astrazeneca
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
